Alzheimer's Association Sets Blood Biomarker Standards for AD Diagnosis

Alzheimer's disease affects an estimated 7.2 million Americans and is projected to double in prevalence by 2060. For decades, in-vivo confirmation of AD pathology required either expensive amyloid PET imaging or invasive (though safe) lumbar puncture for CSF analysis—both largely inaccessible outside major academic centers. The emergence of FDA-regulated blood-based biomarker (BBM) tests has created an urgent need for standardized guidance on when and how these tools should be used clinically.

To address this gap, the Alzheimer's Association convened a multidisciplinary panel of clinicians, subject-matter experts, and methodologists who conducted a systematic review of BBM diagnostic accuracy and applied the GRADE framework to formulate evidence-based recommendations. The guideline targets specialized care settings—memory clinics and neurology practices—where providers are trained in diagnosing memory disorders and where patients presenting with objective cognitive impairment (MCI or dementia) are evaluated.

The BBMs reviewed included plasma p-tau217, %p-tau217 (ratio of phosphorylated to non-phosphorylated tau217 ×100), p-tau181, p-tau231, and the Aβ42/Aβ40 ratio. Reference standards were CSF AD biomarkers, amyloid PET, or neuropathology. The systematic review found that diagnostic accuracy varies considerably across available tests and platforms. P-tau217 and %p-tau217 demonstrated the strongest and most consistent performance, while other analytes showed more variable results.

The guideline issues two performance-based, brand-agnostic recommendations: (1) A BBM achieving ≥90% sensitivity and ≥75% specificity is appropriate as a triage test to stratify patients before more definitive testing; (2) A BBM achieving ≥90% sensitivity and ≥90% specificity may substitute for amyloid PET or CSF biomarker testing in patients with cognitive impairment in specialized care. The panel explicitly notes that many commercially available tests—especially those relying on a single diagnostic cutoff—do not currently meet these thresholds. Multi-threshold testing approaches and biomarker combinations or ratios are highlighted as emerging strategies that may improve accuracy.

Importantly, the guideline stresses that BBMs are not a replacement for comprehensive clinical evaluation. Pretest probability of AD pathology—shaped by patient history, symptom profile, and clinical examination—must inform interpretation of BBM results. The guideline is designed as a living document, with updates planned as the evidence base evolves, and is accompanied by tools and resources to support clinical adoption.